iBio - Die Impfstoffmaschine (Seite 1814)
eröffnet am 16.03.11 21:21:25 von
neuester Beitrag 02.05.24 21:50:27 von
neuester Beitrag 02.05.24 21:50:27 von
Beiträge: 18.250
ID: 1.164.726
ID: 1.164.726
Aufrufe heute: 0
Gesamt: 2.207.226
Gesamt: 2.207.226
Aktive User: 0
ISIN: US4510337086 · WKN: A3E2GR · Symbol: IBIO
1,8800
USD
-1,05 %
-0,0200 USD
Letzter Kurs 02:04:00 NYSE Arca
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,2000 | +93,94 | |
| 1,0300 | +37,44 | |
| 1,3300 | +30,51 | |
| 1,9950 | +27,48 | |
| 21,010 | +26,80 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | -17,81 | |
| 7,5000 | -20,97 | |
| 2,4650 | -27,50 | |
| 4,6600 | -41,60 | |
| 2,0400 | -51,31 |
Beitrag zu dieser Diskussion schreiben
Feedback
ca 2,5 Mio. $ nachbörslich ist nicht viel
die Grossen sind noch nicht investiert
.
http://www.nasdaq.com/symbol/ibio/after-hours
die Grossen sind noch nicht investiert
.
http://www.nasdaq.com/symbol/ibio/after-hours
danke für die info...dann stellt sich nur die frage nach "dem einstieg nach dem anstieg von über 120%...und nachbörslich ging es auch noch über 20 % richtung norden
tantchen
tantchen
Antwort auf Beitrag Nr.: 48.013.780 von Andrew6466 am 12.10.14 18:33:18wie immer
kommt alles zu spät
TAUSENDE müssen erst sterben
bevor Massnamen ergriffen werden
http://www.youtube.com/watch?v=VH-9nx6qS3Q
kommt alles zu spät
TAUSENDE müssen erst sterben
bevor Massnamen ergriffen werden
http://www.youtube.com/watch?v=VH-9nx6qS3Q
schon hier sind Investoren aufgeweckt worden
.
http://motherboard.vice.com/en_ca/read/scientists-are-progra…
.
http://motherboard.vice.com/en_ca/read/scientists-are-progra…
Alt aber gut
NEWARK, DE--(Marketwired - Aug 26, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC. Within two business days of approval of the transaction by the NYSE MKT, Aspire Capital will complete an initial purchase of 1,136,354 shares of common stock at $0.44 per share, the closing sale price of iBio's common stock on the NYSE MKT on the business day prior to entry into the purchase agreement with Aspire Capital, for proceeds of $500,000. After the SEC declares a registration statement effective relating to the transaction, Aspire Capital has committed to purchase up to $9.5 million in additional shares of common stock over a 24 month period. No warrants are associated with this agreement.
"This agreement will enable iBio to sell shares to Aspire Capital from time to time at prices approximating the market price of our shares at the time of each sale," said Robert B. Kay, iBio's CEO. "We believe this agreement is particularly appropriate for iBio at this time. It helps to assure adequate funding for our fibrosis drug development to a point at which efficacy may be demonstrated and will help to enable expansion of our Brazil product partnerships. At the same time, as we work to achieve our various milestones and increase our stock price, this agreement will allow iBio to sell shares at higher prices over time thereby reducing our cost of capital and minimizing dilution."
With a clinical advisory board comprised of leading experts in both idiopathic pulmonary fibrosis (IPF) and systemic sclerosis, iBio is planning to initiate human clinical trials for its proprietary biotherapeutic product for the treatment of fibrosis in early 2015 based on peer-reviewed evidence that specific peptides are useful for both inhibition and reversal of fibrosis in preclinical mouse models of fibrosis and human skin. Additionally, iBio remains focused on advancing its collaboration with Fiocruz and establishing commercial relationships with private sector Brazilian companies in an effort to accelerate the development and commercialization of vaccines and biosimilar therapeutic products in Brazil.
Under the terms of the purchase agreement, iBio will control the timing and amount of any sale of shares of common stock to Aspire Capital. Aspire Capital has no right to require any sales by iBio but is obligated to make purchases as iBio directs, in accordance with the purchase agreement. However, iBio and Aspire Capital may not effect any sales under the purchase agreement on any date where the closing sale price of iBio's common stock is less than $0.44 per share, unless iBio's stockholders approve the transaction contemplated by the purchase agreement. There are no limitations on the use of proceeds, financial covenants or restrictions on future financings and there are no rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement. iBio may terminate the purchase agreement at any time, at its discretion, without any additional cost or penalty.
iBio also entered into a registration rights agreement with Aspire Capital in connection with its entry into the purchase agreement that requires iBio to register the shares sold to Aspire for resale on a new registration statement on Form S-1. A complete and detailed description of the purchase agreement and related registration rights agreement is set forth in the Company's Current Report on Form 8-K, filed today with the SEC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About iBio, Inc.
iBio is developing a proprietary product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases using its iBioLaunch™ platform. The company also offers proprietary products and product licenses to others, based on its proprietary iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. Further information is available at: www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Investor Relations Contact
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
Email Contact
Pipeline
.
NEWARK, DE--(Marketwired - Aug 26, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC. Within two business days of approval of the transaction by the NYSE MKT, Aspire Capital will complete an initial purchase of 1,136,354 shares of common stock at $0.44 per share, the closing sale price of iBio's common stock on the NYSE MKT on the business day prior to entry into the purchase agreement with Aspire Capital, for proceeds of $500,000. After the SEC declares a registration statement effective relating to the transaction, Aspire Capital has committed to purchase up to $9.5 million in additional shares of common stock over a 24 month period. No warrants are associated with this agreement.
"This agreement will enable iBio to sell shares to Aspire Capital from time to time at prices approximating the market price of our shares at the time of each sale," said Robert B. Kay, iBio's CEO. "We believe this agreement is particularly appropriate for iBio at this time. It helps to assure adequate funding for our fibrosis drug development to a point at which efficacy may be demonstrated and will help to enable expansion of our Brazil product partnerships. At the same time, as we work to achieve our various milestones and increase our stock price, this agreement will allow iBio to sell shares at higher prices over time thereby reducing our cost of capital and minimizing dilution."
With a clinical advisory board comprised of leading experts in both idiopathic pulmonary fibrosis (IPF) and systemic sclerosis, iBio is planning to initiate human clinical trials for its proprietary biotherapeutic product for the treatment of fibrosis in early 2015 based on peer-reviewed evidence that specific peptides are useful for both inhibition and reversal of fibrosis in preclinical mouse models of fibrosis and human skin. Additionally, iBio remains focused on advancing its collaboration with Fiocruz and establishing commercial relationships with private sector Brazilian companies in an effort to accelerate the development and commercialization of vaccines and biosimilar therapeutic products in Brazil.
Under the terms of the purchase agreement, iBio will control the timing and amount of any sale of shares of common stock to Aspire Capital. Aspire Capital has no right to require any sales by iBio but is obligated to make purchases as iBio directs, in accordance with the purchase agreement. However, iBio and Aspire Capital may not effect any sales under the purchase agreement on any date where the closing sale price of iBio's common stock is less than $0.44 per share, unless iBio's stockholders approve the transaction contemplated by the purchase agreement. There are no limitations on the use of proceeds, financial covenants or restrictions on future financings and there are no rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement. iBio may terminate the purchase agreement at any time, at its discretion, without any additional cost or penalty.
iBio also entered into a registration rights agreement with Aspire Capital in connection with its entry into the purchase agreement that requires iBio to register the shares sold to Aspire for resale on a new registration statement on Form S-1. A complete and detailed description of the purchase agreement and related registration rights agreement is set forth in the Company's Current Report on Form 8-K, filed today with the SEC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About iBio, Inc.
iBio is developing a proprietary product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases using its iBioLaunch™ platform. The company also offers proprietary products and product licenses to others, based on its proprietary iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. Further information is available at: www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Investor Relations Contact
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
Email Contact
Pipeline
.
Trading Spotlight
Antwort auf Beitrag Nr.: 48.013.834 von Halde20 am 12.10.14 18:51:04das Forum kenne ich nicht
von mir aus können die da posten , was sie wollen
hier könnte ich löschen
.
von mir aus können die da posten , was sie wollen
hier könnte ich löschen
.
Antwort auf Beitrag Nr.: 48.012.973 von gerdass am 12.10.14 16:23:20
Link
http://www.investorvillage.com/smbd.asp?mb=11383&mn=24533&pt…
Message Nr. 24533
Zitat von gerdass:Zitat von Halde20: Hm , ja, alles schon gesehen. Bin noch unschlüssig.
Im USForum wurde schon vom Kauf abgeraten.
Allerdings werden jetzt mehr und mehr drauf aufmerksam. ( Aufrufe dieser Seite sagt ja schon einiges). Kommende Woche geht's sicher erstmal hoch....bis zur 1. Gewinnmitnahme ....
Ich weiß nicht, ich weiß nicht.
geb mir bitte den Link zum
USForum
damit ich es löschen kann
Link
http://www.investorvillage.com/smbd.asp?mb=11383&mn=24533&pt…
Message Nr. 24533
Antwort auf Beitrag Nr.: 48.013.756 von BSA01 am 12.10.14 18:28:27
Schon klar was Du meintest: Hoch oder runter ... aber ich weiß es auch nicht!
Zitat von BSA01: Oh mA, mit abwarten meinte ich, wer Recht behält
Schon klar was Du meintest: Hoch oder runter ... aber ich weiß es auch nicht!
Antwort auf Beitrag Nr.: 48.013.780 von Andrew6466 am 12.10.14 18:33:18es ist eine ganz heisse Aktie
Antwort auf Beitrag Nr.: 48.013.729 von gerdass am 12.10.14 18:20:57
Meine Meinung: Man geht viel zu leichtfertig mit dieser "verseuchten Mikrobe" um, an- und auskleiden nur unter sterilen Bedingungen nach Desinfektion der Schutzkleidung in hermetisch abgeriegelten Kabinen.
By the way: Wie die Amis auf solche Meldungen im eigenen Land in der jüngsten Vergangenheit reagiert haben ist bekannt, bitte anschnallen für morgen!
Andrew
Zitat von gerdass: http://edition.cnn.com/2014/10/12/health/ebola/index.html
Meine Meinung: Man geht viel zu leichtfertig mit dieser "verseuchten Mikrobe" um, an- und auskleiden nur unter sterilen Bedingungen nach Desinfektion der Schutzkleidung in hermetisch abgeriegelten Kabinen.
By the way: Wie die Amis auf solche Meldungen im eigenen Land in der jüngsten Vergangenheit reagiert haben ist bekannt, bitte anschnallen für morgen!
Andrew
Durchsuchen
